ReviewFoods (Basel, Switzerland)2026
Sugarcane Biorefinery from Component Separation to High-Value Outputs: Technical Progress and Future Perspectives.
Review in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
As a major global sugar crop and lignocellulosic feedstock, sugarcane processing traditionally suffers from single-product dependency and low byproduct utilization, causing resource waste and environmental factors. To address this, the 'sugarcane processing tree' framework offers a pathway for full-component valorization. This review systematically summarizes the high-value utilization pathways for sugarcane juice, bagasse, and filter mud. Key quantitative insights reveal that the functional sugars offer high profitability due to premium market prices; bagasse pretreatment constitutes 40-50% of overall biorefinery costs; and crude wax recovery from filter mud stagnates at only 5-8%, limiting commercial scale-up. Current bottlenecks are characterized by low pretreatment efficiency, subpar strain performance, and high isolation costs. Future advancements must integrate coupled biorefining, synthetic biology, and standardized frameworks to spearhead the low-carbon, circular transition of the sugarcane industry for sustainable development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.